Comparison · NCT04676724-sae
GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) vs GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) vs GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks): serious adverse events. Trial comparisons, record NCT04676724-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04676724-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.109 | 0.051 | 0.218 | wilson | |
| Risk in group 2 | 0.0377 | 0.0104 | 0.128 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0714 | -0.0356 | 0.184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.89 | 0.61 | 13.7 | log | |
| Odds ratio, group 1 over group 2 | 3.12 | 0.601 | 16.2 | log | |
Number needed to harm, for one more participant with a serious adverse event on GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) than on GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | Participants on stable NA therapy received 300mg/week GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks. | 6 | 55 | EG000 |
| Group 2 | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks. | 2 | 53 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Week 72
Source ClinicalTrials.gov
Trial
- Title
- Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
- NCT number
- NCT04676724
- Phases
- PHASE2
- Conditions
- Hepatitis B
- Interventions
- GSK3228836, PegIFN, NA therapy
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2024-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04676724?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04676724-sae